雷珠单抗注射液球内注射治疗糖尿病黄斑水肿与常规治疗方法对比观察
A Comparative Study between Conventional Approaches and Intraocular Injection of Ranibizumab in the Treatment of Diabetic Macular Edema
摘要: 目的:探索更为有效,更为经济便捷的DME治疗手段。方法:分析2012年6月至2016年5月就诊于我院的DME患者经激光、玻璃体腔注射雷珠单抗/曲安奈德、玻璃体切割手术治疗的98例104只眼,其中男56例58只眼,女42例46只眼,平均年龄为57岁。结果:各组治疗前后视力和CMT变化情况:1) 玻璃体腔内注射TA,在治疗1月和3月时,患者视力有显著提高,CMT明显降低,差异有显著性(p = 0.000);治疗6月视力稍有提高,CMT较治疗前变化不明显,差异无显著性。2) 玻璃体腔内注射雷珠单抗,在治疗1月时视力显著提高,CMT明显降低,差异有统计学意义(p = 0.001);在治疗3月和6月时,视力略提高,CMT无明显变化,差异无显著性。3) 在接受黄斑区激光光凝和(或)全网膜光凝,视力在治疗1个月时,略下降,差异无显著性;视力在治疗3月和6月时,视力无变化,差异无显著性。CMT在治疗1月和3月时稍减轻,与治疗前无显著性差异;治疗6月时CMT明显减轻,差异有显著性(p = 0.001)。4) 在接受玻璃体切割术治疗1月、3月和6月时,视力均有所提高,差异有显著性(p = 0.001)。CMT在治疗1月时减轻,差异无显著性;在术后3月和6月时,CMT减轻,较治疗前差异有显著性(p = 0.001)。结论:玻璃体腔注射雷珠单抗和注射TA、黄斑区光凝与玻璃体切割术在治疗DME上都是有效的。在提高视力方面,注药和玻璃体切割术更为有效。玻璃体腔注射TA,效果亦较好,但并发白内障、继发青光眼、眼内炎等并发症较多,要权衡治疗效果与风险而慎重选择,对于严重白内障和人工晶体的患者亦不失为一种很好的选择。激光治疗如果作为首选,尽管视网膜水肿可以消退但视力提高不是很明显。玻璃体切割术效果稳定持久,但需要具备特定的手术条件和手术技术,需要掌握好适应症,可以作为治疗黄斑水肿的常见方法。
Abstract: Purpose: The purpose of this research is to uncover a more effective, economical and more conve-nient approach in the treatment of diabetic macular edema (DME). Method: The research is con-ducted by analyzing 98 DME cases with 104 eyes that are treated through laser photocoagulation, intravitreal injection of Ranibizumab, intravitreal injection of triamcinolone (TA) and vitrectomy respectively in the Baotou Eye Hospital from June, 2012 to May, 2016. Among 98 cases with 104 eyes, 56 cases with 58 eyes are male patients while 42 cases with 46 eyes are female patients. The average age of 98 patients are 57. Results: The comparison of eyesight and central macular thick-ness (CMT) before and after treatment with different approaches: 1) In cases that are treated through intravitreal injection of TA, the effectiveness of this approach is significant in the first month and the third month. The eyesight of patients is considerably improved (p = 0.000). More-over, CMT of patients shows a remarkable decrease. However, the effectiveness of TA treatment is no longer significant in the third month and the sixth month. The eyesight of patients is slightly improved and CMT shows no remarkable change. 2) In cases that are treated through intravitreal injection of Ranibizumab, the effectiveness of this approach is statistically significant in the first month and the third month (p = 0.001). The eyesight of patients is considerably improved and CMT shows a remarkable decrease. Similarly, the effectiveness of Ranibizumab is no longer significant in the third month and the sixth month. The eyesight of patients is slightly improved and CMT shows no remarkable change. 3) In cases that are treated through laser photocoagulation in macular region or the whole retinal, the effectiveness of this approach is not significant since the first month. The eyesight of patients is slightly decreased. The effectiveness remained insignificant in the third and sixth month with no remarkable change of eyesight. CMT shows a slight decrease in the first and third month and manifests a statistically significant decrease in the sixth month (p = 0.001). 4) In cases that are treated through vitrectomy, the eyesight of patients is significantly improved in the first, third and sixth month. CMT shows a slight decrease in the first and third month but manifests a significant decrease in the sixth month when compared with the situation before treatment (p = 0.001). Conclusion: Laser photocoagulation, intravitreal injection of Ranibizumab, intravitreal injection of TA and vitrectomy are all effective in the treatment of DME. With respect to eyesight improvement, intravitreal injection and vitrectomy show more significant effectiveness. Although intravitreal injection of TA is considered to be more effective especially for patients with serious cataract or artificial lens when compared with other approaches, the risk of complications of cataract, secondary glaucoma or endophthalmitis is higher. Therefore, it is necessary to balance the effectiveness and potential complications when choosing different approaches. In terms of laser photocoagulation, it is effective to decrease CMT but shows no significant improvement of eyesight. In addition, the effectiveness of vitrectomy is more stable. However, it can only be implemented with specific operation conditions and skills. As a consequence, it can be applied as a conventional approach to treat DME.
文章引用:边红霞, 杨桦, 边梦婷, 刘瑞英, 郭宓, 于学龙, 王淑清, 李凤鸣, 马国敏, 郭永强, 刘伟红. 雷珠单抗注射液球内注射治疗糖尿病黄斑水肿与常规治疗方法对比观察[J]. 眼科学, 2018, 7(1): 39-48. https://doi.org/10.12677/HJO.2018.71007

参考文献

[1] Iklein, R., Klein, B.E. and Moss, S.E. (1991) The Epidemiology of Ocular Problems in Diabetes Mellitus. Blackwell Scientific Pub-lications, Boston, 1-51.
[2] 中华医学会眼科学会眼底病学组黎晓新, 等. 我国糖尿病视网膜病变临床诊疗指南(2014年) [J]. 中华眼科杂志, 2014, 50(11): 851-865.
[3] International Diabetes Federation. IDF Diabetes Atlas. 6th Edition, International Diabetes Federation, Brussels, Belgium.
[4] Wang, F.H., Liang, Y.B., Zhang, F., et al. (2009) Prevalence of Diabetic Retinopathy in Rural China: The Handan Eye Study. Ophthalmology, 116, 461-467.
[Google Scholar] [CrossRef] [PubMed]
[5] Klein, R., Klein, B.E, Moss, S.E., et al. (1984) The Wisconsin Epidemiologic Study of Diabetic Retinopathy II. Prevalence and Risk of Diabetic Relinopathy When Age at Diagnosis Is Less Than 30 Years. Arch Ophthalmology, 102, 520-526.
[Google Scholar] [CrossRef] [PubMed]
[6] Varma, R., Torres, M., Pena, F., et al. (2004) Prevalence of Di-abetic Retinapathy in Adult Lations: The Los Angeles Latino Eye Study. Ophthalmology, 111, 1298-1306.
[Google Scholar] [CrossRef] [PubMed]
[7] Malik, R.A., Lic, A.W., et al. (2005) Elevated Plasma CD 105 and Vitreous VEGF Levels in Diabetic Retinopathy. Journal of Cellular and Molecular Medicine, 9, 692-697.
[Google Scholar] [CrossRef] [PubMed]
[8] Do Carmo, A., Ramos, P., Reis, A., et al. (1998) Breakdown of the Inner and Outer Blood Retinal Barrier in Streptozotocin-Induced Diabetes. Experimental Eye Research, 67, 569-575.
[Google Scholar] [CrossRef] [PubMed]
[9] Witmer, A.N., Vrensen, G.F., Van Noorden, C.J., et al. (2003) Vascular Endothelial Growth Factors and Angiogenesis in Eye Disease. Progress in Retinal and Eye Research, 22, 1-29.
[Google Scholar] [CrossRef
[10] Ramasamy, R., Vannucci, S.J., Yam, S.S., et al. (2006) Advanced Glyca-tion End Products and RAGE: A Common Thread in Aging, Diabetes Neurodegeneration, and Inflammation. Ophthalmology, 113, 1706-1712.
[11] Kim, W., Hudson, B.I., Moser, B., et al. (2005) Receptor for Advanced Glycation End Products and Its Ligands: A Journey from the Complication of Diabetes to Its Pathogenesis. Ann NY Acad Sci, 1043, 553-561.
[Google Scholar] [CrossRef] [PubMed]
[12] Harbour, J.W., Smiddy, W.E., Flynn, H.W.J., et al. (1996) Vitrectomy for Diabetic Macular Edema Associated with a Thickened and Taut Posterior Hyaloidsmembrane. American Journal of Ophthalmology, 121, 405-413.
[Google Scholar] [CrossRef
[13] Porta, M.S. and Banadello, F. (1987) Diabetic Retinopathy Study Research Group Photocoagulation for Diabetic Macular Edema: Early Treatment Diabetic Retinopathy Study Report NO. 4. International Ophthalmology Clinics, 27, 265-272.
[Google Scholar] [CrossRef] [PubMed]
[14] Yamanoto, T., Takeuchi, S., Sato, Y. and Yamashita, H. (2007) Long-Term Follow-Up Results of Pars Plana Vitrectomy for Diabetic Macular Edema. Jpn J Ophthalmol, 51, 285-291.
[15] Americar Diabetes Association (2002) Diabetic Retinopathy. Diabetes Care, 25, 590-593.
[16] Kohner, E.M. (1993) Fortnightly Review: Diabetic Retinopathy. BMJ, 307, 1195-1199.
[Google Scholar] [CrossRef] [PubMed]
[17] Hansson-lundblad, C., Holm, K., Agardh, C.D., et al. (2002) A Small Number of Older Type 2 Diabetic Patients End up Visuslly Impaired Despite Regular Photographic Screening and Laser Treatment for Diabetic Retinopathy. Acta Ophthalmol Scand, 80, 310-315.
[Google Scholar] [CrossRef] [PubMed]
[18] Martidis, A., Duker, J.S., Greenberg, P.B., et al. (2002) Intravitreal Triamcinolone for Refractory Diabetic Macular Edema. Ophthalmology, 109, 920-927.
[Google Scholar] [CrossRef
[19] Gillies, M.C., Sutter, F.K., Simpon, J.M., et al. (2006) Intravitreal Triamcinolone for Refractory Diabetic Macular Edema: Two-Year Results of a Double-Masked, Plracebocontrolled, Randomized Clinical Trial. Ophthalmology, 113, 1533-1538.
[Google Scholar] [CrossRef] [PubMed]
[20] Ockrim, I.K., Senswathi, S., Falk, S., et al. (2006) A Randomized Trial of Intravitreal Triamcinolone versus Macular Oedema Invest Ophthalmol Vis Sci, 47, 5438.
[21] Chun, D.W., Heier, J.S., Tpopping, T.M., et al. (2006) A Pilot Study of Mukltiple Intravitreal Injections of Ranibizumab in Patients with Center-Involving Clinically Significant Diabetic Macular Edema. Ophthalmology, 113, 1706-1712.
[Google Scholar] [CrossRef] [PubMed]
[22] Nguyen, Q.D., Tatlipinar, S., Shah, S.M., et al. (2006) Vascularendothelial Growth Factor Is a Critical Stimulus for Diabetic Macular Edema. American Journal of Ophthalmology, 142, 961-969.
[Google Scholar] [CrossRef] [PubMed]
[23] Gibran, S.K., Khan, K., Jungkim, S. and Cleary, P.E. (2007) Optical Coherence Tomographic Pattern May Predict Visual Outcome after Intravitreal Triamcinolone for Diabetic Macular Edema. Ophthalmology, 114, 890-894.
[Google Scholar] [CrossRef] [PubMed]
[24] Gandorfer, A., Messmer, E.M., UIbig, M.W., et al. (2000) Resolution of Diabetic Macular Edema after Surgical Removal of the Posterior Hyaloid and the Inner Limiting Membrane. Retina, 20, 126-133.
[Google Scholar] [CrossRef
[25] Mochizuki, Y., Hata, Y., Enaida, H., et al. (2006) Evalualting Ad-junctive Surgical Procedures during Vitrectomy for Diabetic Macular Edema. Retina, 26, 143-148.
[Google Scholar] [CrossRef] [PubMed]
[26] Yanyali, A., Horozoglu, F., Celik, E., et al. (2007) Long-Term Out-comes of Pars Plana Vitrectomy with Internal Limiting Membrane Removal in Diabeyic Macular Edema. Relina, 27, 557-566.
[27] Patel, J.I., Hykin, P.G., Schadt, M., et al. (2006) Pars Plana Vitrectomy for Diabetic Macular Edema: OCT and Func-tional Correlations. Eye, 20, 674-680.
[Google Scholar] [CrossRef] [PubMed]
[28] Yamanoto, T., Takeuchi, S., Sato, Y. and Yamashita, H. (2007) Long-Term Follow-Up Results of Pars Plana Vitrectomy for Diabetic Macular Edema. Japanese Journal of Ophthalmology, 51, 285-291.
[Google Scholar] [CrossRef] [PubMed]
[29] Shimomagano, Y., Makiuchi, R., Miyazaki, M., Ethimomagano, Y., Makiuchi, R., Miyazaki, M., et al. (2007) Results of Visual Acuity and Foveal Thickness in Diabetic Macular Edema after Vitrectomy. Japanese Journal of Ophthalmology, 51, 204-209.
[Google Scholar] [CrossRef] [PubMed]